Different culture media affect growth characteristics, surface marker distribution and chondrogenic differentiation of human bone marrow-derived mesenchymal stromal cells

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Hagmann, Sebastien ^a   Moradi, Babak ^a   Frank, Sebastian ^a   Dreher, Thomas ^a   Kämmerer, Peer Wolfgang ^b   Richter, Wiltrud ^a   Gotterbarm, Tobias ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Adipogenic differentiation; Chondrogenic differentiation; Expansion media; Mesenchymal stromal cells; Osteogenic differentiation; Surface markers

Indexed keywords

CD146 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ENDOGLIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; THY 1 ANTIGEN;

ADULT; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CHONDROGENESIS; CULTURE MEDIUM; CYTOMETRY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MESENCHYMAL STROMA CELL; PROTEIN EXPRESSION;

ADULT; ANTIGENS, SURFACE; BIOLOGICAL MARKERS; BIOPSY, FINE-NEEDLE; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHONDROGENESIS; CULTURE MEDIA; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS;

EID: 84880938447     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-223     Document Type: Article

References (50)

1. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Becker AJ, Mc CE, Till JE, Nature 1963 197 452 454 10.1038/197452a0 13970094
2. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA, Exp Hematol 1974 2 83 92 4455512
3. Osteogenesis in transplants of bone marrow cells. Friedenstein AJ, Piatetzky S II, Petrakova KV, J Embryol Exp Morphol 1966 16 381 390 5336210
4. Multilineage cells from human adipose tissue: implications for cell-based therapies. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH, Tissue Eng 2001 7 211 228 10.1089/107632701300062859 11304456 (Pubitemid 32295155)
5. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Bieback K, Kern S, Kluter H, Eichler H, Stem Cells 2004 22 625 634 10.1634/stemcells.22-4-625 15277708 (Pubitemid 39014578)
6. Circulating skeletal stem cells. Kuznetsov SA, Mankani MH, Gronthos S, Satomura K, Bianco P, Robey PG, J Cell Biol 2001 153 1133 1140 10.1083/jcb.153.5.1133 11381097 (Pubitemid 34289251)
7. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. da Silva ML, Chagastelles PC, Nardi NB, J Cell Sci 2006 119 2204 2213 10.1242/jcs.02932 16684817 (Pubitemid 43960310)
8. Pluripotency of mesenchymal stem cells derived from adult marrow. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, et al. Nature 2002 418 41 49 10.1038/nature00870 12077603 (Pubitemid 34742565)
9. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W, Ho AD, Exp Hematol 2005 33 1402 1416 10.1016/j.exphem.2005.07.003 16263424 (Pubitemid 41541969)
10. Quantitative, structural, and image-based mechanical analysis of nonunion fracture repaired by genetically engineered mesenchymal stem cells. Kallai I, van Lenthe GH, Ruffoni D, Zilberman Y, Muller R, Pelled G, Gazit D, J Biomech 2010 43 2315 2320 10.1016/j.jbiomech.2010.04.031 20471652
11. The healing of bony defects by cell-free collagen-based scaffolds compared to stem cell-seeded tissue engineered constructs. Lyons FG, Al-Munajjed AA, Kieran SM, Toner ME, Murphy CM, Duffy GP, O'Brien FJ, Biomaterials 2010 31 9232 9243 10.1016/j.biomaterials.2010.08.056 20863559
12. Cartilage engineering from mesenchymal stem cells. Goepfert C, Slobodianski A, Schilling AF, Adamietz P, Portner R, Adv Biochem Eng Biotechnol 2010 123 163 200 20535603
13. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Guo J, Lin GS, Bao CY, Hu ZM, Hu MY, Inflammation 2007 30 97 104 10.1007/s10753-007-9025-3 17497204 (Pubitemid 46985774)
14. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Feigenbaum GS, Margitich IS, Mazhari R, Boyle AJ, Zambrano JP, Rodriguez JE, et al. Circ Res 2010 107 913 922 10.1161/CIRCRESAHA.110.222703 20671238
15. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Mazhari R, Hare JM, Nat Clin Pract Cardiovasc Med 2007 4 Suppl 1 21 26 17230212
16. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E, Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
17. Xeno-free proliferation of human bone marrow mesenchymal stem cells. Miwa H, Hashimoto Y, Tensho K, Wakitani S, Takagi M, Cytotechnology 2012 64 301 308 10.1007/s10616-011-9400-7 22002865
18. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Reyes M, Lund T, Lenvik T, Aguiar D, Koodie L, Verfaillie CM, Blood 2001 98 2615 2625 10.1182/blood.V98.9.2615 11675329
19. Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Sotiropoulou PA, Perez SA, Salagianni M, Baxevanis CN, Papamichail M, Stem Cells 2006 24 462 471 10.1634/stemcells.2004-0331 16109759 (Pubitemid 44464816)
20. Suitability of human mesenchymal stem cells for gene therapy depends on the expansion medium. Apel A, Groth A, Schlesinger S, Bruns H, Schemmer P, Buchler MW, Herr I, Exp Cell Res 2009 315 498 507 10.1016/j.yexcr.2008.11.013 19084517
21. Proliferation as a requirement for in vitro chondrogenesis of human mesenchymal stem cells. Dexheimer V, Frank S, Richter W, Stem Cells Dev 2012 21 2160 2169 10.1089/scd.2011.0670 22229819
22. Novel markers for the prospective isolation of human MSC. Buhring HJ, Battula VL, Treml S, Schewe B, Kanz L, Vogel W, Ann N Y Acad Sci 2007 1106 262 271 10.1196/annals.1392.000 17395729 (Pubitemid 47443036)
23. Phenotypic characterization of distinct human bone marrow-derived MSC subsets. Buhring HJ, Treml S, Cerabona F, de Zwart P, Kanz L, Sobiesiak M, Ann N Y Acad Sci 2009 1176 124 134 10.1111/j.1749-6632.2009.04564.x 19796240
24. Age related changes in human articular chondrocyte yield, proliferation and post-expansion chondrogenic capacity. Barbero A, Grogan S, Schafer D, Heberer M, Mainil-Varlet P, Martin I, Osteoarthritis Cartilage 2004 12 476 484 10.1016/j.joca.2004.02.010 15135144 (Pubitemid 38696948)
25. Identification of markers to characterize and sort human articular chondrocytes with enhanced in vitro chondrogenic capacity. Grogan SP, Barbero A, Diaz-Romero J, Cleton-Jansen AM, Soeder S, Whiteside R, Hogendoorn PC, Farhadi J, Aigner T, Martin I, Mainil-Varlet P, Arthritis Rheum 2007 56 586 595 10.1002/art.22408 17265493
26. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP, Am J Cardiol 2004 94 92 95 10.1016/j.amjcard.2004. 03.034 15219514 (Pubitemid 38813459)
27. ClinicalTrials.gov by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) http://:www.clinicaltrials.gov 23901030
28. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, Muul L, Hofmann T, Proc Natl Acad Sci U S A 2002 99 8932 8937 10.1073/pnas.132252399 12084934 (Pubitemid 34693661)
29. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W, Bone Marrow Transplant 2002 30 215 222 10.1038/sj.bmt.1703650 12203137 (Pubitemid 35023593)
30. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O, Lancet 2004 363 1439 1441 10.1016/S0140-6736(04)16104-7 15121408 (Pubitemid 38586721)
31. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Mazzini L, Fagioli F, Boccaletti R, Mareschi K, Oliveri G, Olivieri C, Pastore I, Marasso R, Madon E, Amyotroph Lateral Scler Other Motor Neuron Disord 2003 4 158 161 10.1080/14660820310014653 13129802 (Pubitemid 37184884)
32. Comparison of different culture conditions for human mesenchymal stromal cells for clinical stem cell therapy. Haack-Sorensen M, Friis T, Bindslev L, Mortensen S, Johnsen HE, Kastrup J, Scand J Clin Lab Invest 2008 68 192 203 10.1080/00365510701601681 17852829
33. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Fekete N, Gadelorge M, Furst D, Maurer C, Dausend J, Fleury-Cappellesso S, Mailander V, Lotfi R, Ignatius A, Sensebe L, et al. Cytotherapy 2012 14 540 554 10.3109/14653249.2012.655420 22296115
34. Unravelling the retention of proliferation and differentiation potency in extensive culture of human subcutaneous fat-derived mesenchymal stem cells in different media. Dhanasekaran M, Indumathi S, Rashmi M, Rajkumar JS, Sudarsanam D, Cell Prolif 2012 45 516 526 10.1111/j.1365-2184.2012.00843.x 23106299
35. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J, Stem Cells Dev 2012 21 2724 2752 10.1089/scd.2011.0722 22468918
36. Comparative investigation of the differentiation capability of bone-marrow- and adipose-derived mesenchymal stem cells by qualitative and quantitative analysis. Vishnubalaji R, Al-Nbaheen M, Kadalmani B, Aldahmash A, Ramesh T, Cell Tissue Res 2012 347 419 427 10.1007/s00441-011-1306-3 22287041
37. Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRP-derived scaffold for cartilage regeneration. Xie X, Wang Y, Zhao C, Guo S, Liu S, Jia W, Tuan RS, Zhang C, Biomaterials 2012 33 7008 7018 10.1016/j.biomaterials.2012.06.058 22818985
38. Fibroblast growth factor 2 enhances the kinetics of mesenchymal stem cell chondrogenesis. Cheng T, Yang C, Weber N, Kim HT, Kuo AC, Biochem Biophys Res Commun 2012 426 544 550 10.1016/j.bbrc.2012.08.124 22982316
39. Effect of fibroblast growth factor-2 on equine mesenchymal stem cell monolayer expansion and chondrogenesis. Stewart AA, Byron CR, Pondenis H, Stewart MC, Am J Vet Res 2007 68 941 945 10.2460/ajvr.68.9.941 17764407 (Pubitemid 47408323)
40. Expansion in the presence of FGF-2 enhances the functional development of cartilaginous tissues engineered using infrapatellar fat pad derived MSCs. Buckley CT, Kelly DJ, J Mech Behav Biomed Mater 2012 11 102 111 22658159
41. Impact of growth factors and PTHrP on early and late chondrogenic differentiation of human mesenchymal stem cells. Weiss S, Hennig T, Bock R, Steck E, Richter W, J Cell Physiol 2010 223 84 93 20049852
42. Chondrogenesis of human mesenchymal stem cells by local transforming growth factor-beta delivery in a biphasic resorbable carrier. Dickhut A, Dexheimer V, Martin K, Lauinger R, Heisel C, Richter W, Tissue Eng Part A 2010 16 453 464 10.1089/ten.tea.2009.0168 19705961
43. Effect of dual growth factor delivery on chondrogenic differentiation of rabbit marrow mesenchymal stem cells encapsulated in injectable hydrogel composites. Park H, Temenoff JS, Tabata Y, Caplan AI, Raphael RM, Jansen JA, Mikos AG, J Biomed Mater Res A 2009 88 889 897 18381637
44. TGF-beta1 regulates differentiation of bone marrow mesenchymal stem cells. Zhao L, Hantash BM, Vitam Horm 2011 87 127 141 22127241
45. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Chase LG, Yang S, Zachar V, Yang Z, Lakshmipathy U, Bradford J, Boucher SE, Vemuri MC, Stem Cells Transl Med 2012 1 750 758 10.5966/sctm.2012- 0072 23197667
46. Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Lindroos B, Boucher S, Chase L, Kuokkanen H, Huhtala H, Haataja R, Vemuri M, Suuronen R, Miettinen S, Cytotherapy 2009 11 958 972 10.3109/14653240903233081 19903107
47. Isolation, enumeration, and expansion of human mesenchymal stem cells in culture. Wagey R, Short B, Methods Mol Biol 2013 946 315 334 10.1007/978-1-62703-128-8-20 23179841
48. Reduced reactivation from dormancy but maintained lineage choice of human mesenchymal stem cells with donor age. Dexheimer V, Mueller S, Braatz F, Richter W, PLoS One 2011 6 22980 10.1371/journal.pone.0022980 21850247
49. Chondrogenic and immunophenotypic properties of mesenchymal stem cells from osteoarthritis patients (abstract). Hagmann S, Moradi B, Frank S, Bäsig A-M, Dreher T, Richter W, Gotterbarm T, Osteoarthritis Cartilage 2011 20 Suppl. 1 277
50. Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. Phinney DG, Kopen G, Righter W, Webster S, Tremain N, Prockop DJ, J Cell Biochem 1999 75 424 436 10.1002/(SICI)1097-4644(19991201) 75:3<424::AID-JCB8>3.0.CO;2-8 10536366 (Pubitemid 29521651)